Topical rapamycin (sirolimus) for facial angiofibromas
| Autor: | Bhushan Madke |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Facial angiofibromas
business.industry Tuberous sclerosis Pharmacology Mechanism of action lcsh:RL1-803 medicine.disease Pulmonary lymphangiomyomatosis Drug Profile Sirolimus medicine lcsh:Dermatology Rapamycin medicine.symptom Protein kinase A business PI3K/AKT/mTOR pathway medicine.drug Renal angiomyolipoma |
| Zdroj: | Indian Dermatology Online Journal, Vol 4, Iss 1, Pp 54-57 (2013) Indian Dermatology Online Journal |
| ISSN: | 2229-5178 |
| Popis: | Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR. Rapamycin is a novel class of anticancer and immunosuppressant drugs targeting the proteins at molecular level. Rapamycin (sirolimus) is routinely incorporated in drug-eluting stents used for cardiac angioplasty. In recent years, rapamycin was found to be efficacious in managing the symptom complex of tuberous sclerosis, i.e. renal angiomyolipoma, giant cell astrocytoma and pulmonary lymphangiomyomatosis. Various investigators have also proved that topically applied rapamycin causes regression of facial angiofibromas, giving better cosmetic results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|